Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 16Adempas

02 3Alliance revenue - Adempas/Verquvo

PharmaCompass

01

Brand Name : Adempas

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Riociguat

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2020 Revenue in Millions : 760

2019 Revenue in Millions : 506

Growth (%) : 50

Company Banner

02

Brand Name : Adempas

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Riociguat

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2021 Revenue in Millions : 813

2020 Revenue in Millions : 760

Growth (%) : 18

Company Banner

03

Brand Name : Adempas

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Riociguat

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2022 Revenue in Millions : 685

2021 Revenue in Millions : 813

Growth (%) : -16

Company Banner

04

Brand Name : Adempas

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Riociguat

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2023 Revenue in Millions : 716

2022 Revenue in Millions : 685

Growth (%) : 1

Company Banner

05

Brand Name : Adempas

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Riociguat

Main Therapeutic Indication : Cardiology/Vascular Diseases

Currency : USD

2024 Revenue in Millions : 759

2023 Revenue in Millions : 716

Growth (%) : 6

Company Banner

06

Brand Name : Adempas

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Riociguat

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2017 Revenue in Millions : 366

2016 Revenue in Millions : 315

Growth (%) : 16

Company Banner

07

Brand Name : Adempas

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Riociguat

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2018 Revenue in Millions : 402

2017 Revenue in Millions : 333

Growth (%) : 21%

Company Banner

08

Brand Name : Adempas

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBayer AG manufactures innovative APIs and pharmaceutical formulations across diverse therapeutic areas.

Riociguat

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2019 Revenue in Millions : 456

2018 Revenue in Millions : 388

Growth (%) : 17

Company Banner

09

Brand Name : Adempas

Riociguat

arrow
PEGS Boston Summit
Not Confirmed

Brand Name : Adempas

arrow
PEGS Boston Summit
Not Confirmed

Riociguat

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2020 Revenue in Millions : 501

2019 Revenue in Millions : 419

Growth (%) : 20

blank

10

Brand Name : Adempas

Riociguat

arrow
PEGS Boston Summit
Not Confirmed

Brand Name : Adempas

arrow
PEGS Boston Summit
Not Confirmed

Riociguat

Main Therapeutic Indication : Cardiovascular Diseases

Currency : USD

2021 Revenue in Millions : 252

2020 Revenue in Millions : 220

Growth (%) : 15

blank